Harmony Biosciences (HRMY) Competitors

Harmony Biosciences logo
$32.98 -0.04 (-0.11%)
As of 11:18 AM Eastern
This is a fair market value price provided by Massive. Learn more.

HRMY vs. AXSM, LNTH, AMRX, BLTE, and MANE

Should you buy Harmony Biosciences stock or one of its competitors? Harmony Biosciences's main competitors and comparable companies include Axsome Therapeutics (AXSM), Lantheus (LNTH), Amneal Pharmaceuticals (AMRX), Belite Bio (BLTE), and Veradermics (MANE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Harmony Biosciences compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Harmony Biosciences (NASDAQ:HRMY) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

In the previous week, Harmony Biosciences had 5 more articles in the media than Axsome Therapeutics. MarketBeat recorded 16 mentions for Harmony Biosciences and 11 mentions for Axsome Therapeutics. Harmony Biosciences' average media sentiment score of 0.31 beat Axsome Therapeutics' score of 0.15 indicating that Harmony Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Axsome Therapeutics
0 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
2 Very Negative mention(s)
Neutral
Harmony Biosciences
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Harmony Biosciences has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Axsome Therapeutics$638.50M11.20-$183.17M-$3.06N/A
Harmony Biosciences$868.45M2.23$158.69M$3.0210.93

Axsome Therapeutics has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market. Comparatively, Harmony Biosciences has a beta of 1, meaning that its share price has a similar volatility profile to the broader market.

Harmony Biosciences has a net margin of 18.05% compared to Axsome Therapeutics' net margin of -18.18%. Harmony Biosciences' return on equity of 18.55% beat Axsome Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Axsome Therapeutics-18.18% -198.73% -22.03%
Harmony Biosciences 18.05%18.55%13.24%

Axsome Therapeutics currently has a consensus price target of $266.21, indicating a potential upside of 95.82%. Harmony Biosciences has a consensus price target of $48.00, indicating a potential upside of 45.41%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Axsome Therapeutics is more favorable than Harmony Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Axsome Therapeutics
1 Sell rating(s)
2 Hold rating(s)
17 Buy rating(s)
1 Strong Buy rating(s)
2.86
Harmony Biosciences
1 Sell rating(s)
6 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.38

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Comparatively, 11.0% of Harmony Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Harmony Biosciences beats Axsome Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Harmony Biosciences compare to Lantheus?

Harmony Biosciences (NASDAQ:HRMY) and Lantheus (NASDAQ:LNTH) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.

Harmony Biosciences has a net margin of 18.05% compared to Lantheus' net margin of 17.28%. Lantheus' return on equity of 29.26% beat Harmony Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Harmony Biosciences18.05% 18.55% 13.24%
Lantheus 17.28%29.26%15.40%

Harmony Biosciences currently has a consensus target price of $48.00, indicating a potential upside of 45.41%. Lantheus has a consensus target price of $107.44, indicating a potential upside of 5.54%. Given Harmony Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Harmony Biosciences is more favorable than Lantheus.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Harmony Biosciences
1 Sell rating(s)
6 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.38
Lantheus
0 Sell rating(s)
11 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.21

86.2% of Harmony Biosciences shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 11.0% of Harmony Biosciences shares are held by insiders. Comparatively, 1.7% of Lantheus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Harmony Biosciences has a beta of 1, suggesting that its share price has a similar volatility profile to the broader market.Comparatively, Lantheus has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market.

Lantheus has higher revenue and earnings than Harmony Biosciences. Harmony Biosciences is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Harmony Biosciences$868.45M2.23$158.69M$3.0210.93
Lantheus$1.54B4.32$233.56M$4.0625.07

In the previous week, Harmony Biosciences had 11 more articles in the media than Lantheus. MarketBeat recorded 16 mentions for Harmony Biosciences and 5 mentions for Lantheus. Lantheus' average media sentiment score of 0.54 beat Harmony Biosciences' score of 0.31 indicating that Lantheus is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Harmony Biosciences
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Lantheus
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Lantheus beats Harmony Biosciences on 9 of the 16 factors compared between the two stocks.

How does Harmony Biosciences compare to Amneal Pharmaceuticals?

Harmony Biosciences (NASDAQ:HRMY) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

Harmony Biosciences has a net margin of 18.05% compared to Amneal Pharmaceuticals' net margin of 4.17%. Amneal Pharmaceuticals' return on equity of 283.50% beat Harmony Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Harmony Biosciences18.05% 18.55% 13.24%
Amneal Pharmaceuticals 4.17%283.50%7.79%

Harmony Biosciences presently has a consensus target price of $48.00, suggesting a potential upside of 45.41%. Amneal Pharmaceuticals has a consensus target price of $23.00, suggesting a potential upside of 8.90%. Given Harmony Biosciences' higher probable upside, equities analysts clearly believe Harmony Biosciences is more favorable than Amneal Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Harmony Biosciences
1 Sell rating(s)
6 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.38
Amneal Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.80

In the previous week, Harmony Biosciences had 9 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 16 mentions for Harmony Biosciences and 7 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.63 beat Harmony Biosciences' score of 0.31 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Harmony Biosciences
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Amneal Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive

Harmony Biosciences has higher earnings, but lower revenue than Amneal Pharmaceuticals. Harmony Biosciences is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Harmony Biosciences$868.45M2.23$158.69M$3.0210.93
Amneal Pharmaceuticals$3.02B2.44$72.06M$0.4250.29

86.2% of Harmony Biosciences shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 11.0% of Harmony Biosciences shares are held by company insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Harmony Biosciences has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.Comparatively, Amneal Pharmaceuticals has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market.

Summary

Amneal Pharmaceuticals beats Harmony Biosciences on 9 of the 16 factors compared between the two stocks.

How does Harmony Biosciences compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Harmony Biosciences (NASDAQ:HRMY) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

0.5% of Belite Bio shares are held by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are held by institutional investors. 13.3% of Belite Bio shares are held by company insiders. Comparatively, 11.0% of Harmony Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Belite Bio currently has a consensus price target of $226.91, indicating a potential upside of 43.87%. Harmony Biosciences has a consensus price target of $48.00, indicating a potential upside of 45.41%. Given Harmony Biosciences' higher possible upside, analysts clearly believe Harmony Biosciences is more favorable than Belite Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Belite Bio
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.67
Harmony Biosciences
1 Sell rating(s)
6 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.38

Harmony Biosciences has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Belite BioN/AN/A-$77.61M-$2.73N/A
Harmony Biosciences$868.45M2.23$158.69M$3.0210.93

In the previous week, Belite Bio had 7 more articles in the media than Harmony Biosciences. MarketBeat recorded 23 mentions for Belite Bio and 16 mentions for Harmony Biosciences. Belite Bio's average media sentiment score of 0.65 beat Harmony Biosciences' score of 0.31 indicating that Belite Bio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Belite Bio
4 Very Positive mention(s)
6 Positive mention(s)
9 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Harmony Biosciences
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Harmony Biosciences has a net margin of 18.05% compared to Belite Bio's net margin of 0.00%. Harmony Biosciences' return on equity of 18.55% beat Belite Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Belite BioN/A -9.95% -9.76%
Harmony Biosciences 18.05%18.55%13.24%

Belite Bio has a beta of -1.19, meaning that its stock price is 219% less volatile than the broader market. Comparatively, Harmony Biosciences has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.

Summary

Harmony Biosciences beats Belite Bio on 10 of the 15 factors compared between the two stocks.

How does Harmony Biosciences compare to Veradermics?

Veradermics (NYSE:MANE) and Harmony Biosciences (NASDAQ:HRMY) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Veradermics presently has a consensus target price of $174.57, indicating a potential upside of 38.81%. Harmony Biosciences has a consensus target price of $48.00, indicating a potential upside of 45.41%. Given Harmony Biosciences' higher probable upside, analysts plainly believe Harmony Biosciences is more favorable than Veradermics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Veradermics
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67
Harmony Biosciences
1 Sell rating(s)
6 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.38

Harmony Biosciences has a net margin of 18.05% compared to Veradermics' net margin of 0.00%. Harmony Biosciences' return on equity of 18.55% beat Veradermics' return on equity.

Company Net Margins Return on Equity Return on Assets
VeradermicsN/A -20.50% -17.66%
Harmony Biosciences 18.05%18.55%13.24%

86.2% of Harmony Biosciences shares are owned by institutional investors. 11.0% of Harmony Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Harmony Biosciences has higher revenue and earnings than Veradermics. Veradermics is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VeradermicsN/AN/A-$70M-$1.90N/A
Harmony Biosciences$868.45M2.23$158.69M$3.0210.93

In the previous week, Harmony Biosciences had 8 more articles in the media than Veradermics. MarketBeat recorded 16 mentions for Harmony Biosciences and 8 mentions for Veradermics. Veradermics' average media sentiment score of 0.73 beat Harmony Biosciences' score of 0.31 indicating that Veradermics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Veradermics
2 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Harmony Biosciences
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Summary

Harmony Biosciences beats Veradermics on 10 of the 13 factors compared between the two stocks.

Get Harmony Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for HRMY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HRMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HRMY vs. The Competition

MetricHarmony BiosciencesPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.94B$13.42B$7.65B$11.69B
Dividend YieldN/A2.58%2.47%4.46%
P/E Ratio10.9328.7833.9329.91
Price / Sales2.237.298.455.70
Price / Cash10.3615.6321.0121.90
Price / Book1.815.444.473.74
Net Income$158.69M$2.88B$3.51B$393.98M
7 Day Performance-3.64%-4.59%-5.96%-5.71%
1 Month Performance-13.11%-4.27%-4.39%-7.03%
1 Year Performance-2.99%-7.06%-1.32%-7.26%

Harmony Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HRMY
Harmony Biosciences
4.3548 of 5 stars
$32.98
-0.1%
$48.00
+45.6%
-2.9%$1.94B$868.45M10.93293
AXSM
Axsome Therapeutics
3.4751 of 5 stars
$133.96
+1.2%
$267.58
+99.7%
-6.6%$7.21B$638.50MN/A925
LNTH
Lantheus
2.4215 of 5 stars
$101.01
+0.4%
$107.44
+6.4%
+93.9%$6.60B$1.54B20.311,193
AMRX
Amneal Pharmaceuticals
3.3792 of 5 stars
$21.28
+5.7%
$23.00
+8.1%
+82.4%$6.37B$3.02B50.678,500
BLTE
Belite Bio
3.016 of 5 stars
$157.69
+2.3%
$227.40
+44.2%
+34.9%$6.20BN/AN/A41

Related Companies and Tools


This page (NASDAQ:HRMY) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners